Sarepta Therapeutics (SRPT) Stock: Here’s What You Need To Know

Sarepta Therapeutics (NASDAQ:SRPT) On Monday, Sarepta’s stock closed the day up 73.85% after the company announced that the FDA had given its drug Eteplirsen FDA approval. More specifically, the company filed for accelerated approval. In other words, drugs can be approved after only completing a phase 2 study if the results show that a surrogate … Read more